IIB：Other Gastrointestinal tumors

Phase 1Biologic

IIB：Other Gastrointestinal tumors is one of 2 biologic programs targeting Intravenous Administration. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Intravenous AdministrationRecruiting

Intravenous AdministrationPhase 1

Recruiting

Competition

Competitive Landscape

1 competitor in Intravenous Administration

#DrugCompanyPhaseTrials

IDOV-SAFE

FFudan University

Phase 1

1 2

IIB：Other Gastrointestinal tumors

PPeking University

Phase 1

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2027

Phase 1Recruiting

Intravenous Administration

NCT06380309

Clinical

Trials by Indication[1]

Intravenous Administration1 trial

A Clinical Study on Evaluating Intravenous Administration of IDOV-SAFE

Recruiting·PPeking University·Phase 1·NCT06380309·89 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for IIB：Other Gastrointestinal tumors. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — IIB：Other Gastrointestinal tumors compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for IIB：Other Gastrointestinal tumors. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Peking University company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Phase 1[1]
Company: PPeking University

IIB：Other Gastrointestinal tumors

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2027

Trials by Indication[1]

Intravenous Administration1 trial

References

Drug Info

Quick Facts

Related News